The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response
Fernanda I. Arnaldez(MacroGenics (United States)), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Walter J. Urba(Providence Portland Medical Center), Bingqing Fu(University of Science and Technology of China), Vincenzo Montesarchio(CTO Hospital), Jeffrey S. Weber(NYU Langone Health), Jon M. Wigginton(Bristol-Myers Squibb (United States)), Steven O’Day(Saint John's Health Center), Bernard A. Fox(Oregon Health & Science University), Charles G. Drake(Columbia University Irving Medical Center), Haiming Wei(University of Science and Technology of China)
Cited by 93
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k